Patients with cancer can develop recurrent metastatic disease with latency periods that
range from years even to decades. This pause can be explained by cancer dormancy, a …

The development of metastasis is the major cause of death in cancer patients. In certain
instances, this occurs shortly after primary tumor detection and treatment, indicating these …

Abstract Dasatinib (BMS-354825), a novel dual SRC/BCR-ABL kinase inhibitor, exhibits
greater potency than imatinib mesylate (IM) and inhibits the majority of kinase mutations in …

Disseminated tumor cells (DTCs) are recognized as the seeds of metastasis. However,
metastatic lesions can become symptomatic years or decades after primary tumor removal …

Allogeneic stem cell transplantation (SCT) plays a central role in chronic myeloid leukemia
(CML) because it remains the only treatment with proven curative potential. For this reason …

The monitoring of minimal residual disease (MRD) through low sensitivity real-time (RT)
polymerase chain reaction (PCR) analysis of BCR-ABL transcripts allows early detection of …

Experimental findings support the hypothesis that within the functional network of the bone
marrow (BM) microenvironment the endothelial cells (ECs) exert a pivotal role as …

Metastasis is responsible for the vast majority of cancer-related deaths. However, our
understanding of this complex process is still vastly limited, as is the ability to prevent …

Imatinib (Gleevec)(formerly STI571) has been shown to selectively inhibit the tyrosine kinase
domain of the oncogenic BCR-ABL fusion protein of chronic myelogenous leukemia (CML) …

Scant knowledge is available about the dynamics of lineage-specific mixed chimerism (Ch)
following bone marrow transplantation (BMT). This review is focused on findings derived …